Use of antithrombotic agents during pregnancy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Chest

Volumn 126, Issue 3 SUPPL., 2004, Pages 627S-644S

  Bates, Shannon M ^b   Greer, Ian A ^b   Hirsh, Jack ^b   Ginsberg, Jeffrey S ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b NONE

Author keywords

Antithrombotic; Low molecular weight heparin; Obstetrics; Pregnancy; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; COUMARIN; COUMARIN DERIVATIVE; DALTEPARIN; DANAPAROID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; THROMBIN INHIBITOR; TINZAPARIN; WARFARIN;

ABORTION; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; FIBRINOLYTIC THERAPY; HEART VALVE PROSTHESIS; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; META ANALYSIS; NONHUMAN; OSTEOPOROSIS; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; PUERPERIUM; RISK FACTOR; SIDE EFFECT; SOLUTIO PLACENTAE; SYSTEMATIC REVIEW; TERATOGENESIS; THIRD TRIMESTER PREGNANCY; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 4644258310     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.3_suppl.627S     Document Type: Conference Paper

References (121)

1. The National Institute for Clinical Excellence, Scottish Executive Health Department and Department of Health, Social Services and Public Safety: Northern Ireland. Confidential Enquiries into Maternal Deaths in the United Kingdom 1997-99. London: TSO, 2001. Available at: http:// www.cemach.org.uk/ publications/CEMDreports/cemdrpt. pdfhttp://www.cemach.org.uk/publications/ CEMDreports/ cemdrpt.pdf. Accessed July 2003
2. Hull RD, Raskob GF, Carter CJ. Serial IPG in pregnancy patients with clinically suspected DVT: clinical validity of negative findings. Ann Intern Med 1990; 112:663-667
3. Hull RD, Hirsh J, Carter C, et al. Diagnostic efficacy of IPG for clinically suspected DVT: a randomized trial. Ann Intern Med 1985; 102:21-28
4. Hull RD, Hirsh J, Sackett D, et al. Diagnostic efficacy of IPG in suspected venous thrombosis: an alternative to venography. N Engl J Med 1977; 296:1497-1500
5. Lensing AWA, Prandoni P, Brandjes D, et al. Detection of DVT by real-time B-mode ultrasonography. N Engl J Med 1989; 320:342-345
6. Ginsberg JS, Kearon C, Douketis J, et al. D-dimer and impedance plethysmography in patients with suspected deep vein thrombosis: results of a management trial. Arch Intern Med 1997; 157:1077-1081
7. Chan WS, Ray JG, Murray S, et al. Suspected pulmonary embolism in pregnancy: clinical presentation, results of lung scanning, and subsequent maternal and pediatric outcomes Arch Intern Med 2002; 162:1170-1175
8. PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA 1990; 263:2753-2759
9. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest 1985; 88:819-828
10. Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scot Med J 1996; 41:83-86
11. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353:1258-1265
12. Ginsberg JS, Brill-Edwards P, Burrows RF, et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992; 67:519-520
13. Cockett FB, Thomas ML, Negus D. Iliac vein compression: its relation to iliofemoral thrombosis and the post-thrombotic syndrome. BMJ 1967; 2:14-16
14. Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77:39-43
15. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176:1062-1068
16. Blomback M, Bremme K, Hellgren M, et al. Thromboprophylaxis with low molecular mass heparin, "Fragmin" (dalteparin), during pregnancy: longitudinal safety study. Blood Coagul Fibrinolysis 1998; 9:1-9
17. Blomback M, Bremme K, Hellgren M, et al. A pharmacokinetic study of dalteparin during late pregnancy. Blood Coagul Fibrinolysis 1998; 9:343-350
18. Brennand JE, Walker ID, Greer IA. Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin. Acta Haematol 1999; 101:53-55
19. Dulitzki M, Pauzner R, Langevitz P, et al. Low molecular weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 87:380-383
20. Casele HL, Laifer SA, Woelkers DA, et al. Changes in the phannacokinetics of the low molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181:1113-1117
21. Ellison J, Walker ID, Greer IA. Antifactor Xa profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin for prevention and treatment of thromboembolism in pregnancy. Br J Obstet Gynaecol 2000; 107:1116-1121
22. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol 2001; 108:1134-1140
23. Dolovich L, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low molecular weight heparins to unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160:181-188
24. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130:800-809
25. de Valek HW, Banga JD, Wester JWJ, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism: a randomized controlled trial. Ann Intern Med 1995; 123:1-9
26. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopedic surgery: a meta-analysis. Lancet 1992; 340:152-156
27. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-698
28. Nelson-Piercy C, Letsky EA, et al. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176:1062-1068
29. Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res 1984; 34:557-560
30. Forestier F, Daffos F, Rainaut M, et al. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy [letter]. Thromb Haemost 1987; 57:234
31. Sanson BJ, Lensing AWA, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81:668-672
32. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335
33. Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications for coumarin. Thromb Haemost 1994; 71:7-11
34. Pettila V, Leinonen P, Markkola A, et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87:182-186
35. Mora A, Belch J, Contreras L, et al. Delayed-type hypersensitivity skin reactions to low molecular weight heparins in a pregnant woman. Contact Dermatitis 2002; 47:177-178
36. Flessa HC, Klapstrom AB, Glueck MJ, et al. Placental transport of heparin. Am J Obstet Gynecol 1965; 93:570-573
37. Ginsberg JS, Hirsh J, Turner CD, et al. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989; 61:197-203
38. Ginsberg JS, Kowalchuk G, Hirsh J, et al. Heparin therapy during pregnancy: Risks to the fetus and mother. Arch Intern Med 1989; 149:2233-2236
39. Hall JAG, Paul RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68:122-140
40. Wesseling J, van Driel D, Heymans HAS, et al. Coumarins during pregnancy: long term effects on growth and development in school age children. Thromb Haemost 2001; 85:609-613
41. Hull RD, Delmore TJ, Carter CJ, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306:189-194
42. Hull RD, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307:1676-1681
43. Chunilal SD, Young E, Johnston MA, et al. The aPTT response of pregnant plasma to unfractionated heparin. Thromb Haemost 2000; 87:92-97
44. Anderson DR, Ginsberg JS, Burrows R, et al. Subcutaneous heparin therapy during pregnancy: a need for concern at the time of delivery. Thromb Haemost 1991; 63:248-250
45. Farquarson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomised controlled trial of treatment. Obstet Gynecol 2002; 100:408-413
46. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70:554-561
47. Douketis JD, Ginsberg JS, Burrows RF, et al. The effects of long-term heparin therapy during pregnancy on bone density. Thromb Haemost 1996; 75:254-257
48. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168:1265-1270
49. Muir J, Andrew M, Hirsh J, et al. Histomorpbometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 1996; 88:1314-1320
50. Sbaughnessy SG, Hirsh J, Bhandari M, et al. Histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Blood 1999; 93:1231-1236
51. Muir JM, Hirsh J, Weitz JI, et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 1997; 89:3236-3242
52. O'Reilly R. Anticoagulant, antithrombotic and thrombolytic drugs. In: Gillman AG, Goodman LS, Gilman A, eds. The pharmacologic basis of therapeutics, 6th ed. New York, NY: Macmillan, 1980; 1347
53. Orme L'E, Lewis M, de Swiet M, et al. May mothers given warfarin breast-feed their infants? BMJ 1977; 1:1564-1565
54. McKenna R, Cole ER, Vasan V. Is warfarin sodium contraindicated in the lactating mother? J Pediatr 1983; 103:325-327
55. Imperiale TF, Petrulis AS. A meta-analysis of low-dose aspirin for prevention of pregnancy-induced hypertensive disease. JAMA 1991; 266:260-264
56. CLASP Collaborative Group. CLASP: a randomised trial of low dose aspirin for the prevention and treatment of preeclampsia among 9,364 pregnant women. Lancet 1994; 343:619-629
57. Lopaciuk S, Bilska-Falda H, Noszczyk W, et al. Low-molecular-weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999; 81:26-31
58. Pini M, Aiello S, Manotti C, et al. Low-molecular-weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72:191-197
59. van der Heijden JF, Hutten BA, Buller HR, et al. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2000(4):CD002001
60. Crowther MA, Spitzer K, Julian J, et al. Pharmacokinetic profile of a low-molecular weight (Reviparin) in pregnant patients: a prospective cohort study. Thromb Res 2000; 98:133-138
61. Rodie VA, Thomson AJ, Stewart FM, et al. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: case series. Br J Obstet Gynaecol 2002; 109:1020-1024
62. Thomson AJ, Greer, IA. Thromboembolic disease in pregnancy and the puerperium: Acute management. Royal College of Obstetricians and Gynaecologists, London, Guideline No 20, 2001. Available at: http:www.rcog.org.uk/guidelines. asp?PageID=106&GuidelineID=20). Accessed July 2003
63. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venons thromboembolism in patients with cancer. N Engl J Med 2003; 349:146-153
64. De Swiet M, Floyd E, Letsky E. Low risk of recurrent thromboembolism in pregnancy [letter]. Br J Hosp Med 1987; 38:264
65. Howell R, Fidler J, Letsky E, et al. The risk of antenatal subcutaneous heparin prophylaxis: a controlled trial. Br J Obstet Gynecol 1983; 90:1124-1128
66. Badaracco MA, Vessey M. Recurrent venous thromboembolic disease and use of oral contraceptives. BMJ 1974; 1:215-217
67. Tengborn L. Recurrent thromboembolism in pregnancy and puerperium: is there a need for thromboprophylaxis? Am J Obstet Gynecol 1989; 160:90-94
68. Brill-Edwards P, Ginsberg JS, for the Recurrence Of Clot In This Pregnancy (ROCIT) Study Group. Safety of withholding antepartum heparin in women with a previous episode of venous thromboembolism. N Engl J Med 2000; 343:1439-1444
69. Pettila V, Kaaja R, Leinonen P, et al. Thromboprophylaxis with low-molecular-weight heparin "dalteparin" in pregnancy. Thromb Res 1999; 96:275-282
70. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318:1162-1173
71. Gerhardt A, Scharf RE, Beckman MW, et al. Prothrombin and factor V mutations in women with thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342:374-380
72. McColl M, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 8:1183-1188
73. McColl MD, Ellison J, Reid F, et al. Prothrombin 20210GA, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol 2000; 107:567-569
74. Martinelli I, de Stefano V, Taioli E, et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002; 87:791-795
75. Friederich PW, Sanson B-J, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125:955-960
76. Long AA, Ginsberg JS, Brill-Edwards P, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 1991; 66:520-524
77. Middledorp S, Van der Meer J, Hamulyak K, et al. Counselling women with factor V Leiden homozygosity: use absolute instead of relative risks. Thromb Haemost 2001; 87:360-361
78. Middledorp S, Libourel EJ, Hamulyak K, et al. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol 2001; 113:553-555
79. Martinelli I, Legnani C, Bucciarelli P, et al. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001; 86:800-803
80. Pabinger I, Nemes L, Rintelen C, et al. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J 2000; 1:37-41
81. Den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia as a risk for deep-vein thrombosis. N Engl J Med 1995; 334:759-762
82. Grandone E, Margaglione M, Colaizzo D, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998; 179:1324-1328
83. Greer IA. The challenge of thrombophilia in maternal-fetal medicine. N Engl J Med 2000; 342:424-425
84. Report of the RCOG Working Party on prophylaxis against thromboembolism in gynaecology and obstetrics. London, UK: Royal College of Obstetricians and Gynaecologists, 1995
85. Hague WM, North RA, Callus AS, et al. Anticoagulation in pregnancy and the puerperium. Med J Aust 2001; 175:258-263
86. Gates S, Brocklehurst P, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period (Cochrane Review). Cochrane Database Syst Rev. 2002; (2):CD001689
87. Kupfermine MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 341:9-13
88. Nelen WL, Steegers EA, Eskes TK, et al. Genetic risk factor for unexplained recurrent early pregnancy loss [letter]. Lancet 1997; 350:861
89. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348:913-916
90. Sanson BJ, Friederich PW, Simioni P, et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996; 75:387-388
91. Murphy RP, Donoghue C, Nallen RJ. Prospective evaluation of the risk conferred by Factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000; 20:266-270
92. Younis JS, Brenner B, Ohel G. Activated protein C resistance and factor V Leiden mutation can be associated with first as well as second trimester recurrent pregnancy loss. Am J Reprod Immunol 2000; 43:31-35
93. Gris JC, Quere I, Monpeyroux F, et al. Case-control study of the frequency of thrombophilic disorders in couples with late fetal loss and no thrombotic antecedent: the Nimes Obstetricians and Haematologists Study 5(NOHA5). Thromb Haemost 1999; 81:891-899
94. Martinelli JR, Taioli E, Cetin I, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343:1015-1018
95. Rai R, Shlebak A, Cohen H, et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001; 16:961-965
96. Pihusch R, Buchholz T, Lohse P, et al. Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol 2001; 46:124-131
97. Reznikoff-Etievan MF, Cayol V, Carbonne B, et al. Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. Br J Obstet Gynaecol 2001; 108:1251-1254
98. Nelen WL, Blom HJ, Steegers EA, et al. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril 2000; 74:1196-1199
99. Rey E, Kahn SR, David M, et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361:901-908
100. Alferivic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome. Eur J Obstet Gyencol Reprod Biol 2002; 101:6-14
101. Morrison ER, Miedzybrodzka ZH, Campbell D, et al. Prothrombotic genotypes are not associated with preeclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002; 87:779-785
102. Infante-Rivard C, Rivard GE, Wagner VYH, et al. Absence of association of thrombophilic polymorphism with intrauterine growth restriction. N Engl J Med 2002; 347:19-25
103. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112:682-698
104. Ginsberg JS, Brill-Edwards P, Johnston M, et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood 1992; 80:975-980
105. Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337:148-153
106. Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314:253-257
107. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174:1584-1589
108. a TaLima F, Khamashta MA, Buchananans, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14:131-136
109. b Backos M, Rai R, Baxter N, et al. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol 1999; 106:102-107
110. Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve prostheses. Br Heart J 1994; 71:196-201
111. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic-review of the literature. Arch Intern Med 2000; 160:191-196
112. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin. Ann Intern Med 1993; 119:104-109
113. Arnaout MS, Kazma H, Khalil A, et al. Is there a safe anticoagulation protocol for pregnant women with prosthetic valves? Clin Exp Obstet Gynecol 1998; 25:101-104
114. Lee LH, Liauw PC, Ng AS. Low molecular weight heparin for thromboprophylaxis during pregnancy in 2 patients with mechanical mitral valve replacement [letter]. Thromb Haemost 1996; 76:628-630
115. Rowan JA, McCowan LM, Raudkivi PJ, et al. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol 2001; 185:633-637
116. Roberts N, Ross D, Flint SK, et al. Thromboembolism in pregnant women with mechanical prosthetic heart valves anticoagulated with low molecular weight heparin. Br J Obstet Gynaecol 2001; 108:327-329
117. Leyh RG, Fischer S, Ruhparwar A, et al. Anticoagulation for prosthetic heart valves during pregnancy: is low-molecular-weight heparin an alternative. Eur J Cardiothorac Surg 2002; 21:577-579
118. Mahesh B, Evans S, Bryan AJ. Failure of low molecular-weight heparin in the prevention of prosthetic mitral valve thrombosis during pregnancy: case report and review of options for anticoagulation. J Heart Valve Dis 2002; 11:745-750
119. Lev-Ran O, Kramer A, Gurevitch J, et al. Low-molecular-weight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg 2000; 69:264-265
120. Lovenox Injection (package insert). Bridgewater, NJ: Aventis Pharmaceutical, 2004
121. Turpie AGG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329:524-529